Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPD | P32754 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072863 | 0.94 | HPD (0.50) | ALDH1A1MAPTHPDMEN1KMT2A | |
| SCHEMBL6487862 | 0.86 | ALDH1A1 (0.55) | ALDH1A1MAPTHPDMEN1KMT2A | |
| SCHEMBL6487852 | 0.86 | ALDH1A1 (0.55) | ALDH1A1MAPTHPDMEN1KMT2A | |
| SCHEMBL6072903 | 0.84 | HPD (0.47) | ALDH1A1MAPTHPDMEN1KMT2A | |
| SCHEMBL3363361 | 0.84 | MAPT (0.50) | ALDH1A1MAPTMEN1KMT2APKM | |
| SCHEMBL997302 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPTHPDMEN1KMT2A | |
| SCHEMBL8492650 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAPTHPDMEN1KMT2A | |
| SCHEMBL8492645 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAPTHPDMEN1KMT2A | |
| SCHEMBL5205743 | 0.81 | PKM (0.45) | ALDH1A1MAPTMEN1KMT2APKM | |
| SCHEMBL395222 | 0.81 | PKM (0.45) | ALDH1A1MAPTMEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377958-B2 | Lonidamine analogues for fertility management | THE UNIVERSITY OF KANSAS (US) | 2013-02-19 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2502624-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | THE UNIVERSITY OF KANSAS (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2451783-A2 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | University Of Kansas (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS | 2011-03-10 | — | — | US | disclosed |
| WO-2011005759-A2 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100063301-A1 | SYNTHESIS OF THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS | LIGAND PHARMACEUTICALS INC (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| EP-2001845-A2 | SYNTHESIS OF THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007106564-A2 | SYNTHESIS OF THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-02 | — | — | US | disclosed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063301-A1 | SYNTHESIS OF THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS | MPL, THPO, TBXAS1 | ALDH1A1 3289/4885MAPT 4801/4885HPD 3678/4885 |
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | TRAP1, HSPE1, HSF1 | ALDH1A1 1663/4885MAPT 3368/4885HPD 4461/4885 |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | ALDH1A1 983/4885MAPT 4627/4885HPD 1916/4885 |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, RAF1 | ALDH1A1 2184/4885MAPT 4829/4885HPD 3903/4885 |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | ALDH1A1 983/4885MAPT 4627/4885HPD 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.